Company Description

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States.

The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.

The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.

GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

GlucoTrack, Inc.

Country	United States
Founded	2001
Industry	Medical Devices
Sector	Healthcare
Employees	15
CEO	Erik Emerson

Contact Details

Address: 301 Route 17 North, Suite 800 Rutherford, New Jersey 07070 United States
Phone	201 842 7715
Website	glucotrack.com

Stock Details

Ticker Symbol	GCTK
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1506983
CUSIP Number	45824Q804
ISIN Number	US45824Q8042
Employer ID	98-0668934
SIC Code	3841

Key Executives

Name	Position
Erik C. Emerson	Chief Executive Officer and Director
Dr. Paul V. Goode Ph.D.	Chief Technical Officer, President and Director
Avner Gal MBA, MSc.EE	Co-Founder, Chairman Emeritus and Consultant
David Malka BA	Co-Founder
Vincent Wong	Chief Operations Officer
Dr. Mark Tapsak Ph.D.	Chief Scientific Officer
Drinda Benjamin	Chief Commercial Officer

Latest SEC Filings

Date	Type	Title
Aug 14, 2026	10-Q	Quarterly Report
Aug 10, 2026	DEF 14A	Other definitive proxy statements
Aug 10, 2026	8-K	Current Report
Aug 5, 2026	8-K	Current Report
Jul 31, 2026	PRE 14A	Other preliminary proxy statements
Jul 30, 2026	8-K	Current Report
Jul 29, 2026	8-K/A	[Amend] Current report
Jul 27, 2026	8-K	Current Report
Jul 17, 2026	ARS	Filing
Jul 17, 2026	DEF 14A	Other definitive proxy statements

View All SEC Filings